1-4 of 4
Marion Smits
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study

Thijs van der Vaart, Maarten M.J. Wijnenga, Karin van Garderen, Hendrikus J. Dubbink, Pim J. French, Marion Smits, Clemens M.F. Dirven, Johan M. Kros, Arnaud J.P.E. Vincent, Martin J. van den Bent
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3837–3844.
https://doi.org/10.1158/1078-0432.CCR-24-0901
Published: 03 September 2024
View article titled, Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study
Open the PDF for Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study in another window
Includes: Supplementary data
Journal Articles

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Kaspar Draaisma, C. Mircea S. Tesileanu, Iris de Heer, Martin Klein, Marion Smits, Jaap C. Reijneveld, Paul M. Clement, Filip Y.F. de Vos, Antje Wick, Paul J. Mulholland, Martin J.B. Taphoorn, Michael Weller, Olivier L. Chinot, Johan M. Kros, Tina Verschuere, Corneel Coens, Vassilis Golfinopoulos, Thierry Gorlia, Ahmed Idbaih, Pierre A. Robe, Martin J. van den Bent, Pim J. French
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2440–2448.
https://doi.org/10.1158/1078-0432.CCR-21-3725
Published: 01 June 2022
View article titled, Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
Open the PDF for Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial in another window
Includes: Supplementary data
Journal Articles

Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm

Sebastian R. van der Voort, Fatih Incekara, Maarten M.J. Wijnenga, Georgios Kapas, Mayke Gardeniers, Joost W. Schouten, Martijn P.A. Starmans, Rishie Nandoe Tewarie, Geert J. Lycklama, Pim J. French, Hendrikus J. Dubbink, Martin J. van den Bent, Arnaud J.P.E. Vincent, Wiro J. Niessen, Stefan Klein, Marion Smits
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (24): 7455–7462.
https://doi.org/10.1158/1078-0432.CCR-19-1127
Published: 13 December 2019
View article titled, Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm
Open the PDF for Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm in another window
Includes: Supplementary data
Journal Articles

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

Benjamin M. Ellingson, Elizabeth R. Gerstner, Marion Smits, Raymond Y. Huang, Rivka Colen, Lauren E. Abrey, Dana T. Aftab, Gisela M. Schwab, Colin Hessel, Robert J. Harris, Ararat Chakhoyan, Renske Gahrmann, Whitney B. Pope, Kevin Leu, Catalina Raymond, Davis C. Woodworth, John de Groot, Patrick Y. Wen, Tracy T. Batchelor, Martin J. van den Bent, Timothy F. Cloughesy
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5745–5756.
https://doi.org/10.1158/1078-0432.CCR-16-2844
Published: 01 October 2017
View article titled, Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials
Open the PDF for Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials in another window